Open an account

MaxCyte

MXCT · NASDAQ

$1.43+$0.13 (+10.00%)TodayMarket closed ·
Prev close $1.30

About MXCT

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 91 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Employees
91
Headquarters
Rockville, Maryland
Listed
Mar 29, 2016
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
maxcyte.com

MXCT key statistics

Market cap
147.58M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.18M
Volume
1.39M
Open price
$1.29
High today
$1.46
Low today
$1.29
52 Week high
$1.81
52 Week low
$0.6434

MaxCyte (MXCT) at a glance

As of Oct 20, 2026, MaxCyte (MXCT) shares are priced at $1.43, giving the company a market cap of 147.58M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.29 and $1.46. The current price is 10.9% above the day's low and 1.8% below its high.

Volume so far is 1.39M shares, in line with the average of 1.18M shares a day.

Over the past year MaxCyte has ranged from $0.6434 to $1.81, and now sits 68% of the way up that range.

MaxCyte met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.0918.

The average analyst price target is $4.19, 193.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $4.19
Low
$2.45
Now
$1.43
High
$5.25

MXCT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 21.3% on average.

  1. Q3 FY24: reported -$0.11 per share against an estimate of -$0.1258
  2. Q4 FY24: reported -$0.10 per share against an estimate of -$0.1244
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.1071
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.1054
  5. Q3 FY25: reported -$0.09 per share against an estimate of -$0.1122
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.0816
  7. Q1 FY26: reported -$0.04 per share against an estimate of -$0.0816
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.0918

MXCT news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseBusiness Wire

    Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

  • Press releaseBusiness Wire

    Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Similar companies

Companies in the same industry as MaxCyte

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.